Coherus Oncology, Inc. (NASDAQ:CHRS) Stock Short Interest Report for October

Coherus Oncology, Inc. (NASDAQ:CHRS) saw a large drop in short interest in the month of October. As of October 15th, there was short interest totaling 12,452,177 shares, a drop of 46.6% from the September 30th total of 23,337,539 shares. Approximately 8.7% of the company’s stock are short sold. Based on an average daily trading volume, of 1,579,236 shares, the short-interest ratio is currently 7.9 days.

Coherus Oncology Price Performance

NASDAQ:CHRS traded down $0.08 during trading hours on Monday, reaching $0.75. The company had a trading volume of 2,608,623 shares, compared to its average volume of 1,507,807. Coherus Oncology has a one year low of $0.75 and a one year high of $2.62. The firm has a market capitalization of $115.78 million, a PE ratio of -0.73 and a beta of 1.03. The stock has a 50-day moving average of $1.20 and a two-hundred day moving average of $1.53. The company has a quick ratio of 1.70, a current ratio of 1.77 and a debt-to-equity ratio of 0.61.

Coherus Oncology (NASDAQ:CHRS) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.06. The business had revenue of $14.31 million for the quarter, compared to analyst estimates of $14.41 million. Coherus Oncology had a negative return on equity of 222.75% and a negative net margin of 259.41%. Analysts forecast that Coherus Oncology will post -0.88 earnings per share for the current year.

Hedge Funds Weigh In On Coherus Oncology

A number of large investors have recently bought and sold shares of CHRS. Spark Investment Management LLC acquired a new stake in Coherus Oncology in the second quarter valued at $25,000. Jefferies Financial Group Inc. bought a new stake in Coherus Oncology during the second quarter worth $353,000. Corient Private Wealth LP bought a new stake in shares of Coherus Oncology during the 2nd quarter valued at approximately $140,000. Bank of America Corp DE bought a new stake in Coherus Oncology during the 2nd quarter worth $424,000. Finally, Hsbc Holdings PLC bought a new position in shares of Coherus Oncology during the second quarter valued at $131,000. Institutional investors and hedge funds own 72.82% of the company’s stock.

Analyst Ratings Changes

CHRS has been the subject of a number of analyst reports. HC Wainwright initiated coverage on Coherus Oncology in a research report on Thursday. They issued a “buy” rating for the company. Weiss Ratings upgraded shares of Coherus Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, October 26th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $11.00.

Coherus Oncology Company Profile

Coherus Oncology, formerly known as Coherus BioSciences, is a commercial-stage biopharmaceutical company focused primarily on developing and commercializing medicines for cancer and other serious diseases. The company has built its business around biologic therapies, including biosimilars and innovative treatments intended to improve access to important medicines.

Its portfolio includes UDENYCA (pegfilgrastim-cbq), a long-acting treatment used to reduce the risk of infection associated with chemotherapy, and LOQTORZI (toripalimab-tpzi), an immuno-oncology therapy approved in the United States for certain patients with nasopharyngeal carcinoma.